Personalis Reports Second Quarter 2026 Results and Recent Highlights
Personalis (Nasdaq: PSNL) reported Q2 2026 results for the quarter ended June 30. Clinical tests rose 199% to 10,384. Clinical revenue increased 442% to $2.6 million, while total revenue grew 30% to $22.4 million. The company said it secured Medicare coverage for NeXT Personal in additional IO and neoadjuvant breast cancer indications and ended the quarter with about $212.7 million in cash.
How this was made
The 30-second read
Why it matters
Q2 results show accelerating clinical testing and revenue growth, while Medicare coverage approvals for two additional indications provide a concrete reimbursement-driven pathway to sustain ordering. The Tempus merger announcement also changes how investors will underwrite forward performance (no quarterly guidance/call).
Market read
Traders get a fresh reimbursement catalyst (two Medicare coverage approvals) alongside a strong Q2 print (clinical tests, clinical revenue, and total revenue growth), but deal-related guidance removal adds uncertainty.
What to watch
Clinical test volume growth may be partly timing-driven by newly covered indications and specimen receipt cycles; population sequencing revenue declined slightly, suggesting not all segments are accelerating.
Background
Personalis is a precision oncology genomics company selling NeXT Personal for MRD and recurrence detection, with reimbursement expansion as a key adoption lever.
Ticker impact
Personalis reported Q2 2026 results and said Medicare coverage expanded NeXT Personal IO monitoring and neoadjuvant breast cancer indications.
Likely positive bias for PSNL as reimbursement-driven ordering can accelerate, though merger uncertainty may cap upside.
The article provides concrete Q2 financial/volume figures plus two specific Medicare coverage approvals, both directly tied to future covered testing revenue. It also notes the Tempus merger will remove quarterly guidance, which can increase valuation uncertainty.
Market effects
Reimbursement expansion for MRD and ctDNA-style assays can improve read-through demand expectations for precision oncology diagnostics and companion testing workflows.
Limited direct regional impact; primarily affects US reimbursement and oncology testing adoption.
Moderate, as Medicare coverage can strengthen evidence packages and adoption narratives for international payer discussions.
Counterpoint
The merger with Tempus removes quarterly guidance and can shift investor focus from near-term execution to deal risk, potentially muting the immediate reaction to Q2 strength.
Key entities
- companyPersonalis, Inc.
Reported Q2 2026 financial and operational results and Medicare coverage approvals for NeXT Personal.
- companyTempus AI, Inc.
Announced merger agreement with Personalis; Personalis will stop providing financial guidance and hold no quarterly earnings call.
- productNeXT Personal
Personalis assay platform; Medicare coverage expanded for IO monitoring and neoadjuvant breast cancer monitoring.
- clinical studyVICTORI study
Prospective study cited showing NeXT Personal detected 100% of patient relapses in colorectal cancer recurrence detection.
- clinical studyTRACERx study
Cited evidence on sub-10 ppm sensitivity in lung cancer and recurrence risk implications.
